SYP and early-onset autosomal dominant Alzheimer disease: In a separate study, the co-encapsulation of epigallocatechin-3-gallate and acetyl acid (EGCG/AA NPs), which was orally administered to an APPswe/PS1dE9 mice model for Alzheimer’s disease, led to an upregulation of synaptophysin (SYP) and influenced neuroinflammation, Aβ plaque burden, and the cortical levels of both soluble and insoluble Aβ(1–42) peptides, leading to an improvement in learning and memory [109].